Published Online: Sunday, July 1, 2007

The final guidelines to accelerate the development and production of vaccines to prevent bird flu and seasonal strains of influenza have been approved.

Proposed in March 2006, the recommendations were crafted to help manufacturers use newer technology that allows vaccines to be made more quickly once a strain of flu is identified, and to encourage more companies to get involved in making vaccines.

Under the final recommendations, the FDA outlined steps for companies wanting approval using new manufacturing methods such as cell cultures or advanced genetic technology.

The agency said that companies using either method would have to provide data from clinical trials. Companies interested in pursuing new technology, however, could test vaccines against various predictors of how well a product works and conduct trials later to confirm results.

Latest Articles
Having trouble getting your hands on FluMist?
Novartis is paying $390 million to settle charges that it paid kickbacks to pharmacies to encourage drug sales.
Anxiety sensitivity has been linked to more debilitating asthma symptoms and greater functional limitations.
Nasal corticosteroid sprays do not seem to be viable treatments for the common cold.
Latest Issues